Volume 35, Issue 11 (12-2024)
Studies in Medical Sciences 2024, 35(11): 873-881 |
Back to browse issues page
Research code: 1
Ethics code: IR.UMSU.HIMAM.REC.1402.104
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mahmoodlou R, Hoseinzadeh P, Hoseini F, Hooshmand L. EVALUATION OF THE CORRELATION BETWEEN HEMATOLOGICAL PARAMETERS AND THYROID CANCER IN PATIENTS WITH THYROID NODULES. Studies in Medical Sciences 2024; 35 (11) :873-881
URL: http://umj.umsu.ac.ir/article-1-6345-en.html
URL: http://umj.umsu.ac.ir/article-1-6345-en.html
Assistant Professor, Endocrinology Subspecialist, Urmia University of Medical Sciences, Urmia, Iran (Corresponding Author) , laya.hooshmand58@gmail.com
Abstract: (449 Views)
Background & Aims: Scientific evidence has shown that there is a correlation between thyroid diseases and cancers and some hematological parameters. This study aimed to determine the relationship between hematological markers and thyroid cancer in patients with thyroid nodules visiting Imam Khomeini Hospital in Urmia.
Materials & Methods: In this cross-sectional study, 114 patients diagnosed with thyroid cancer of the FTC (follicular thyroid carcinoma) and PTC (papillary thyroid carcinoma) types and 128 individuals with benign thyroid nodules were included as the control group. Hematological parameters, including hemoglobin level, platelet count, mean platelet volume, lymphocyte count, and neutrophil count, were measured before the initiation of any treatment in the patients. The independent t-test and logistic regression were used to compare the two groups and to establish the relationship between thyroid cancer and hematological parameters.
Results: There was no significant difference between the two groups in terms of gender and age
(p > 0.05). The average hemoglobin level in patients with thyroid cancer was significantly lower than in the control group (12.85 ± 1.58 vs. 13.51 ± 1.79, p = 0.003), while other parameters did not show a significant difference (p > 0.05). A hemoglobin drop below 12.85 in patients with thyroid cancer was identified as an effective threshold, with the risk of low hemoglobin being 1.28 times higher in patients with thyroid cancer compared to the control group. Other parameters were not identified as significant.
Conclusion: A low initial hemoglobin level can be proposed as a preliminary diagnostic parameter for patients with thyroid cancer. The odds ratio of thyroid cancer incidence in patients with Hb less than 12.85 g/dL is 1.28 times higher than in others (p: 0.004).
Materials & Methods: In this cross-sectional study, 114 patients diagnosed with thyroid cancer of the FTC (follicular thyroid carcinoma) and PTC (papillary thyroid carcinoma) types and 128 individuals with benign thyroid nodules were included as the control group. Hematological parameters, including hemoglobin level, platelet count, mean platelet volume, lymphocyte count, and neutrophil count, were measured before the initiation of any treatment in the patients. The independent t-test and logistic regression were used to compare the two groups and to establish the relationship between thyroid cancer and hematological parameters.
Results: There was no significant difference between the two groups in terms of gender and age
(p > 0.05). The average hemoglobin level in patients with thyroid cancer was significantly lower than in the control group (12.85 ± 1.58 vs. 13.51 ± 1.79, p = 0.003), while other parameters did not show a significant difference (p > 0.05). A hemoglobin drop below 12.85 in patients with thyroid cancer was identified as an effective threshold, with the risk of low hemoglobin being 1.28 times higher in patients with thyroid cancer compared to the control group. Other parameters were not identified as significant.
Conclusion: A low initial hemoglobin level can be proposed as a preliminary diagnostic parameter for patients with thyroid cancer. The odds ratio of thyroid cancer incidence in patients with Hb less than 12.85 g/dL is 1.28 times higher than in others (p: 0.004).
References
1. Azangou-Khyavy M, Saeedi Moghaddam S, Rezaei N, Esfahani Z, Rezaei N, Azadnajafabad S, et al. National, sub-national, and risk-attributed burden of thyroid cancer in Iran from 1990 to 2019. Sci Rep 2022;12(1):13231. [DOI:10.1038/s41598-022-17115-0] [PMID] []
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72(1):7-33. [DOI:10.3322/caac.21332] [PMID]
3. Kitahara CM, Schneider AB. Epidemiology of thyroid cancer. Cancer Epidemiol Biomarkers Prev 2022;31(7):1284-97. [DOI:10.1158/1055-9965.EPI-21-1440] [PMID] []
4. Delam H, Bazrafshan M-R, Eidi A. Thyroid cancer in the world: An epidemiological review. J Health Sci Surveill Syst 2020;8(2):63-8. [URL:]
5. Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol 2022;10(4):264-72. [DOI:10.1016/S2213-8587(22)00035-3] [PMID]
6. Porter A, Wong DJ. Perspectives on the treatment of advanced thyroid cancer: approved therapies, resistance mechanisms, and future directions. Front Oncol 2021;10:592202. [DOI:10.3389/fonc.2020.592202] [PMID] []
7. Kartikasari AE, Huertas CS, Mitchell A, Plebanski M. Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. Front Oncol 2021;11:692142. [DOI:10.3389/fonc.2021.692142] [PMID] []
8. Chen Y, Wang W, Zhang X, Yu X, Xi K, Wen Y, et al. Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer. Cancer Manag Res 2018:5411-22. [DOI:10.2147/CMAR.S177320] [PMID] []
9. Lee DS. Clinical implications of the serum platelet-to-lymphocyte ratio in the modern radiation oncology era: research update and literature review. Radiat Oncol 2024;19(1):107. [DOI:10.1186/s13014-024-02485-8] [PMID] []
10. Yaylaci S, Tosun O, Sahin O, Genc AB, Aydin E, Demiral G, et al. Lack of variation in inflammatory hematological parameters between benign nodular goiter and papillary thyroid cancer. Asian Pac J Cancer Prev 2016;17(4):2321-3. [DOI:10.7314/APJCP.2016.17.4.2321] [PMID]
11. Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. Ann Lab Med 2019;39(4):345-57. [DOI:10.3343/alm.2019.39.4.345] [PMID] []
12. Dorgalaleh A, Mahmoodi M, Varmaghani B, Kia OS, Alizadeh S, Tabibian S, et al. Effect of thyroid dysfunctions on blood cell count and red blood cell indices. Iran J Pediatr Hematol Oncol 2013;3(2):73. [PMID: 24575274] [PMCID: PMC3915449]
13. Loredana P, Mele C, Sama MT, Marco Z, Caputo M, De Marchi L, et al. Thyroid cancer phenotypes in relation to inflammation and autoimmunity. Front Biosci 2018;23(12):2267-82. [DOI:10.2741/4705] [PMID]
14. Gong W, Yang S, Yang X, Guo F. Blood preoperative neutrophil-to-lymphocyte ratio is correlated with TNM stage in patients with papillary thyroid cancer. Clinics 2016;71:311-4. [DOI:10.6061/clinics/2016(06)04] [PMID]
15. Jiang C, Wu Y, Huang J, Wang Y, Cong H. Clinical value of complete blood count ratio in benign and malignant thyroid diseases. Cancer Epidemiol 2024;92:102636. [DOI:10.1016/j.canep.2024.102636] [PMID]
16. Kutluturk F, Gul SS, Sahin S, Tasliyurt T. Comparison of mean platelet volume, platelet count, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in the euthyroid, overt hypothyroid and subclinical hyperthyroid phases of papillary thyroid carcinoma. Endocr Metab Immune Disord Drug Targets 2019;19(6):859-65. [DOI:10.2174/1871530319666190206125545] [PMID] []
17. Gamal GG, Zannoun M, Mohamed SA, Mohamed GA. Relation between thyroid function and iron deficiency anemia in primary school-age children: A controlled cross-sectional study. Int J Med Arts 2021;3(4):1855-61. [DOI:10.21608/ijma.2021.83720.1336]
18. Hashim NA, Abdullah YJ, Sayhood AA. Evaluate the hematologic parameters, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in patients with autoimmune hypothyroidism from Amara City, Southern Iraq. Med J Babylon 2023;20(Suppl 1):S48-S52 . [DOI:10.4103/MJBL.MJBL_369_22]
19. Lee KH, Seok EY, Kim EY, Yun JS, Park YL, Park CH. Different prognostic values of individual hematologic parameters in papillary thyroid cancer due to age-related changes in immunity. Ann Surg Treat Res 2019;96(2):70-7. [DOI:10.4174/astr.2019.96.2.70] [PMID] []
20. Cheong TY, Hong SD, Jung K-W, So YK. The diagnostic predictive value of neutrophil-to-lymphocyte ratio in thyroid cancer adjusted for tumor size. PLoS One 2021;16(5):e0251446 . [DOI:10.1371/journal.pone.0251446] [PMID] []
21. Sengul D, Sengul I. Are there any variation in neutrophil lymphocyte ratio, mean platelet volume and platelet count between papillary thyroid cancer and benign nodular thyroid diseases. Sanamed 2018;13(1):11-6. [DOI:10.24125/sanamed.v13i1.209]
22. Aslan M, Cicek MT. A comparison of the platelet index, neutrophil-lymphocyte and platelet-lymphocyte ratios of patients with differentiated thyroid cancer and nodular hyperplasia. Ann Med Res 2021;28(8):12-23. [DOI:10.5455/annalsmedres.2021.03.241]
23. Mihson HS, Maikhan AK, Shuwelif AR. The role of neutrophil to lymphocyte and platelet to lymphocyte ratios in diagnosing thyroid nodule. Mustansiriya Med J 2022;21(2):155-6. [DOI:10.4103/mj.mj_46_22]
24. Bostan H, Sencar ME, Calapkulu M, Hepsen S, Akhanli P, Duger H, et al. The predictive value of hematologic parameters in the risk of thyroid malignancy in cases with atypia/follicular lesion of undetermined significance. Eur Arch Otorhinolaryngol 2022;279(8):4077-84. [DOI:10.1007/s00405-021-07248-9] [PMID]
25. Ahmed SS, Mohammed AA. Effects of thyroid dysfunction on hematological parameters: Case controlled study. Ann Med Surg 2020;57:52-5. [DOI:10.1016/j.amsu.2020.07.008] [PMID] []
26. Liu J, Wang X, Huang L, Li Y, Chen M. Prevalence and temporal trends of anemia in patients with thyroid disease: 1999-2018 NHANES. Endocr Metab Sci 2024;16:100198. [DOI:10.1016/j.endmts.2024.100198]
27. Chen X, Wang H-y, Yu L, Liu J-q, Sun H. Correlation of multiple peripheral blood parameters with metastasis and invasion of papillary thyroid cancer: a retrospective cohort study. 2024. [DOI:10.21203/rs.3.rs-5330530/v1]
28. Stanciu AE, Verzia A, Stanciu MM, Zamfirescu A, Gheorghe DC. Analysis of the correlation between the radioactive iodine activity and neutrophil-to-lymphocyte ratio in patients with differentiated thyroid cancer. Cancers 2022;14(8):1899. [DOI:10.3390/cancers14081899] [PMID] []
29. Demir AN, Kara Z, Sulu C, Uysal S, Zulfaliyeva G, Atar OA, et al. The effect of radioiodine therapy on blood cell count in patients with differentiated thyroid cancer. Hormones 2023;22(4):595-602. [DOI:10.1007/s42000-023-00479-x] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
